The Well Dressed Woman Considers Art Principles

The well dressed woman knows WHAT TO PUT ON, HOW TO PUT IT ON, AND WHEN TO WEAR IT. She has studied her own features and figure, as well as her personality, and knows exactly what lines, materials and colors. will help to bring out her best points. Still more important, she knows her personal defects, and then carefully seeks to obscure or disguise them as far as possible

The Iowa Homemaker vol.1, no.11

Table of Contents Do They Practice What They Preach? by Helen Easter, page 1 The Well Dressed Woman Considers Art Principles by Anne Prang, page 2 Tell Me a Story Mother by Mildred Elder, page 3 The House That Was Built to Fit by Beth Crowley, page 4 A Few Fine Points in Meal Planning by Beth Bailey, page 5 Choosing the Right Picture for the Right Place by Joanna Hansen, page 6 Wherein Refinishing Makes Refurnishing Easy by Glenna Hesse, page 7 What Kind of Kitchen Surfaces Have You? By Glenna Hesse, page 1

The Well Dressed Woman Considers Art Principles

The well dressed woman knows WHAT TO PUT ON, HOW TO PUT IT ON, AND WHEN TO WEAR IT. She has studied her own features and figure, as well as her personality, and knows exactly what lines, materials and colors. will help to bring out her best points. Still more important, she knows her personal defects, and then carefully seeks to obscure or disguise them as far as possible.</p

The Iowa Homemaker vol.1, no.11

Table of Contents Do They Practice What They Preach? by Helen Easter, page 1 The Well Dressed Woman Considers Art Principles by Anne Prang, page 2 Tell Me a Story Mother by Mildred Elder, page 3 The House That Was Built to Fit by Beth Crowley, page 4 A Few Fine Points in Meal Planning by Beth Bailey, page 5 Choosing the Right Picture for the Right Place by Joanna Hansen, page 6 Wherein Refinishing Makes Refurnishing Easy by Glenna Hesse, page 7 What Kind of Kitchen Surfaces Have You? By Glenna Hesse, page 10</p

One-year safety and tolerability profile of pridopidine in patients with Huntington disease

Objective: To assess the 1-year safety profile of the dopaminergic stabilizer pridopidine in patients with Huntington disease. Methods: Patients received pridopidine 45 mg/day for 4 weeks then pridopidine 90 mg/day for 22 weeks in this 6-month open-label extension (OLE) of the 6-month MermaiHD randomized controlled trial (RCT). Any adverse events (AEs) were recorded. Patients were categorized by their RCT treatment group (placebo, pridopidine 45 mg/day, pridopidine 90 mg/day). Results: Of the 386 patients who completed the RCT, 353 entered the OLE and 305 (86.4%) completed. In 1 year, similar percentages of patients from each group reported ≥1 AE (placebo, 79.6% [n = 90/113]; 45 mg/day, 80.8% [n = 101/125]; 90 mg/day, 82.6% [n = 95/115]) and ≥1 serious AE (8.0% [n = 9/113], 12.8% [n = 16/125], and 8.7% [n = 10/115], respectively). The AE profile across both studies was similar; falls and worsening of chorea were most commonly reported. During the OLE, more patients previously receiving pridopidine reported ≥1 AE (67.9% [n = 163/240]) than those who had received placebo (56.6% [n = 64/113]). Early in the RCT, small increases in heart rate were reported in patients receiving pridopidine. During 1 year, no clinically meaningful changes in laboratory parameters or EKG-related safety concerns were identified. Conclusion: Pridopidine (≤90 mg/day) has an acceptable safety profile and is well-tolerated for 1 year. Classification of evidence: This study provides Class IV evidence that pridopidine (≤90 mg/day) is generally safe and well-tolerated in patients with Huntington disease for up to 1 year